Superstring Capital Sells $6.6M Stake in UroGen Pharma Amid Stock Surge

Superstring Capital Management sold a significant stake of 330,983 shares in UroGen Pharma (NASDAQ:URGN) during Q1 2026 for an estimated $6.64 million based on average quarterly pricing. The stock has surged over 600% year-to-date and outperformed the S&P 500 by a wide margin.

By Jonathan Ponciano, The Motley Fool Sun, May 24, 2026 at 1:40 AM GMT+3 4 min read · Yahoo Finance · May 23, 2026, 22:40 UTC

Superstring Capital Sells $6.6M Stake in UroGen Pharma Amid Stock Surge

Tickers: $URGN

Topics: 13F reportable AUM SEC filing Superstring Capital Management UroGen Pharma

Read the full article at Yahoo Finance

More World news

Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC